Expansion Therapeutics has been hard at work raising funds in order to fight genetic disorders according to Scott Rocklage, Managing Partner of 5AM Ventures. Specifically, his firm along with Sanofi Ventures, Kleiner Perkins, and Novartis Venture Fund all contributed to financing the research for DM1 or myotonic dystrophy type 1.
DM1 or myotonic dystrophy type 1 is the main cause of muscular dystrophy in adults. All of the members of a family can be affected by this disorder, and following generations face even worse manifestations of the disorder. There is currently no effective treatment for DM1/myotonic dystrophy type 1.
Expansion Therapeutics partnered with Dr. Scott Rocklage not only to fight the above-mentioned disorder but, are currently working on a plan to develop medicines that target RNA. They are committed to working together in order to develop medications for patients who are without options.
In addition to holding the Managing Partner of 5AM position, Dr. Rocklage has 30+ years of experience in the healthcare management field. Due to his efforts, three medications received FDA approval(Cubicin, Omniscan, and Teslascan). He has also been involved in many other clinical trials regarding the submission of medications for approval.
Dr. Rocklage’s past healthcare management experience includes serving as Chairman and CEO of Cubist Pharmaceuticals. Previous to that he held the position of President and CEO of Nycomed Salutar. He has also held various research and development positions.
Dr. Rocklage completed his B.S. in Chemistry at the University of California, Berkeley, and his Ph.D. in Chemistry at MIT. He worked in the laboratory of Nobel Prize winner Richard R. Schrock while attending MIT. His is currently located in the Boston office of 5AM.
Visit http://5amventures.com/team/scott-m-rocklage-phd/ to learn more.